{"id":"https://openalex.org/W7224680461","doi":"https://doi.org/10.2147/dddt.s631473","title":"First-in-Human Phase 1 Evaluation of the DegradaBALL Mesoporous Silica Nanoparticle Delivery System: An mRNA SARS-CoV-2 Vaccine Study in Healthy Korean Adult Volunteers","display_name":"First-in-Human Phase 1 Evaluation of the DegradaBALL Mesoporous Silica Nanoparticle Delivery System: An mRNA SARS-CoV-2 Vaccine Study in Healthy Korean Adult Volunteers","publication_year":2026,"publication_date":"2026-10-01","ids":{"openalex":"https://openalex.org/W7224680461","doi":"https://doi.org/10.2147/dddt.s631473","pmid":"https://pubmed.ncbi.nlm.nih.gov/42979471","pmcid":"https://www.ncbi.nlm.nih.gov/pmc/articles/13729766"},"language":"en","primary_location":{"id":"doi:10.2147/dddt.s631473","doi":"https://doi.org/10.2147/dddt.s631473","is_oa":true,"landing_page_url":"https://doi.org/10.2147/dddt.s631473","pdf_url":"https://www.dovepress.com/article/download/121547","source":{"id":"https://openalex.org/S2496126384","display_name":"Drug Design Development and Therapy","issn_l":"1177-8881","issn":["1177-8881"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Design, Development and Therapy","raw_type":"journal-article"},"volume":null,"type":"article","is_traditional":true,"indexed_in":["crossref","doaj","pubmed"],"open_access":{"is_oa":true,"oa_status":"gold","oa_url":"https://www.dovepress.com/article/download/121547","any_repository_has_fulltext":true},"authorships":[{"author_position":"first","author":{"id":"https://openalex.org/A5002826539","display_name":"Sooyoun Lee","orcid":"https://orcid.org/0009-0000-3211-4166","observed_orcids":["https://orcid.org/0009-0000-3211-4166"]},"institutions":[{"id":"https://openalex.org/I139264467","display_name":"Seoul National University","ror":"https://ror.org/04h9pn542","country_code":"KR","type":"education","lineage":["https://openalex.org/I139264467"]},{"id":"https://openalex.org/I2802835388","display_name":"Seoul National University Hospital","ror":"https://ror.org/01z4nnt86","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I139264467","https://openalex.org/I2802835388"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Sooyoun Lee","raw_affiliation_strings":["Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea"],"raw_orcid":"https://orcid.org/0009-0000-3211-4166","affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea","institution_ids":["https://openalex.org/I139264467","https://openalex.org/I2802835388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5017969197","display_name":"Ki Young Huh","orcid":"https://orcid.org/0000-0002-1872-9954","observed_orcids":["https://orcid.org/0000-0002-1872-9954"]},"institutions":[{"id":"https://openalex.org/I139264467","display_name":"Seoul National University","ror":"https://ror.org/04h9pn542","country_code":"KR","type":"education","lineage":["https://openalex.org/I139264467"]},{"id":"https://openalex.org/I2802835388","display_name":"Seoul National University Hospital","ror":"https://ror.org/01z4nnt86","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I139264467","https://openalex.org/I2802835388"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Ki Young Huh","raw_affiliation_strings":["Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea"],"raw_orcid":"https://orcid.org/0000-0002-1872-9954","affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea","institution_ids":["https://openalex.org/I139264467","https://openalex.org/I2802835388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5076937960","display_name":"Kyung\u2010Sang Yu","orcid":"https://orcid.org/0000-0003-0921-7225","observed_orcids":["https://orcid.org/0000-0003-0921-7225"]},"institutions":[{"id":"https://openalex.org/I139264467","display_name":"Seoul National University","ror":"https://ror.org/04h9pn542","country_code":"KR","type":"education","lineage":["https://openalex.org/I139264467"]},{"id":"https://openalex.org/I2802835388","display_name":"Seoul National University Hospital","ror":"https://ror.org/01z4nnt86","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I139264467","https://openalex.org/I2802835388"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Kyung-Sang Yu","raw_affiliation_strings":["Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea"],"raw_orcid":"https://orcid.org/0000-0003-0921-7225","affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea","institution_ids":["https://openalex.org/I139264467","https://openalex.org/I2802835388"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5030453441","display_name":"Dal\u2010Hee Min","orcid":"https://orcid.org/0000-0001-8623-6716","observed_orcids":["https://orcid.org/0000-0001-8623-6716"]},"institutions":[{"id":"https://openalex.org/I139264467","display_name":"Seoul National University","ror":"https://ror.org/04h9pn542","country_code":"KR","type":"education","lineage":["https://openalex.org/I139264467"]},{"id":"https://openalex.org/I4210136009","display_name":"Lemonex (South Korea)","ror":"https://ror.org/040qscd03","country_code":"KR","type":"company","lineage":["https://openalex.org/I4210136009"]}],"countries":["KR"],"is_corresponding":false,"raw_author_name":"Dal-Hee Min","raw_affiliation_strings":["Department of Chemistry, Seoul National University, Seoul, Republic of Korea","Lemonex Inc., Institute of Biotherapeutics Convergence Technology, Seoul, Republic of Korea"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Department of Chemistry, Seoul National University, Seoul, Republic of Korea","institution_ids":["https://openalex.org/I139264467"]},{"raw_affiliation_string":"Lemonex Inc., Institute of Biotherapeutics Convergence Technology, Seoul, Republic of Korea","institution_ids":["https://openalex.org/I4210136009"]}]},{"author_position":"middle","author":{"id":"https://openalex.org/A5103266397","display_name":"Cheolhee Won","orcid":"https://orcid.org/0000-0002-4844-1070","observed_orcids":["https://orcid.org/0000-0002-4844-1070"]},"institutions":[{"id":"https://openalex.org/I4210136009","display_name":"Lemonex (South Korea)","ror":"https://ror.org/040qscd03","country_code":"KR","type":"company","lineage":["https://openalex.org/I4210136009"]}],"countries":["KR"],"is_corresponding":true,"raw_author_name":"Cheolhee Won","raw_affiliation_strings":["Lemonex Inc., Institute of Biotherapeutics Convergence Technology, Seoul, Republic of Korea"],"raw_orcid":null,"affiliations":[{"raw_affiliation_string":"Lemonex Inc., Institute of Biotherapeutics Convergence Technology, Seoul, Republic of Korea","institution_ids":["https://openalex.org/I4210136009"]}]},{"author_position":"last","author":{"id":"https://openalex.org/A5064370332","display_name":"In\u2010Jin Jang","orcid":"https://orcid.org/0000-0002-8384-3139","observed_orcids":["https://orcid.org/0000-0002-8384-3139"]},"institutions":[{"id":"https://openalex.org/I139264467","display_name":"Seoul National University","ror":"https://ror.org/04h9pn542","country_code":"KR","type":"education","lineage":["https://openalex.org/I139264467"]},{"id":"https://openalex.org/I2802835388","display_name":"Seoul National University Hospital","ror":"https://ror.org/01z4nnt86","country_code":"KR","type":"healthcare","lineage":["https://openalex.org/I139264467","https://openalex.org/I2802835388"]}],"countries":["KR"],"is_corresponding":true,"raw_author_name":"In-Jin Jang","raw_affiliation_strings":["Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea"],"raw_orcid":"https://orcid.org/0000-0002-8384-3139","affiliations":[{"raw_affiliation_string":"Department of Clinical Pharmacology and Therapeutics, Seoul National University College of Medicine and Hospital, Seoul, Republic of Korea","institution_ids":["https://openalex.org/I139264467","https://openalex.org/I2802835388"]}]}],"institutions":[],"countries_distinct_count":1,"institutions_distinct_count":3,"corresponding_author_ids":["https://openalex.org/A5064370332","https://openalex.org/A5103266397"],"corresponding_institution_ids":["https://openalex.org/I139264467","https://openalex.org/I2802835388","https://openalex.org/I4210136009"],"apc_list":{"value":2836,"currency":"USD","value_usd":2836},"apc_paid":{"value":2836,"currency":"USD","value_usd":2836},"fwci":0.0,"has_fulltext":true,"cited_by_count":0,"citation_normalized_percentile":{"value":0.83801273,"is_in_top_1_percent":false,"is_in_top_10_percent":false},"cited_by_percentile_year":null,"biblio":{"volume":"Volume 20","issue":null,"first_page":"1","last_page":"15"},"is_retracted":false,"is_paratext":false,"is_xpac":false,"primary_topic":{"id":"https://openalex.org/T10118","display_name":"SARS-CoV-2 and COVID-19 Research","score":0.9702000021934509,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},"topics":[{"id":"https://openalex.org/T10118","display_name":"SARS-CoV-2 and COVID-19 Research","score":0.9702000021934509,"subfield":{"id":"https://openalex.org/subfields/2725","display_name":"Infectious Diseases"},"field":{"id":"https://openalex.org/fields/27","display_name":"Medicine"},"domain":{"id":"https://openalex.org/domains/4","display_name":"Health Sciences"}},{"id":"https://openalex.org/T10725","display_name":"RNA Interference and Gene Delivery","score":0.01640000008046627,"subfield":{"id":"https://openalex.org/subfields/1312","display_name":"Molecular Biology"},"field":{"id":"https://openalex.org/fields/13","display_name":"Biochemistry, Genetics and Molecular Biology"},"domain":{"id":"https://openalex.org/domains/1","display_name":"Life Sciences"}},{"id":"https://openalex.org/T10063","display_name":"Nanoparticle-Based Drug Delivery","score":0.0020000000949949026,"subfield":{"id":"https://openalex.org/subfields/2502","display_name":"Biomaterials"},"field":{"id":"https://openalex.org/fields/25","display_name":"Materials Science"},"domain":{"id":"https://openalex.org/domains/3","display_name":"Physical Sciences"}}],"keywords":[{"id":"https://openalex.org/keywords/mesoporous-silica-nanoparticles","display_name":"mesoporous silica nanoparticles","score":0.9929999709129333},{"id":"https://openalex.org/keywords/mrna-vaccine-delivery","display_name":"mRNA vaccine delivery","score":0.9179999828338623},{"id":"https://openalex.org/keywords/sars-cov-2-receptor-binding-domain","display_name":"SARS-CoV-2 receptor-binding domain","score":0.9210000038146973},{"id":"https://openalex.org/keywords/booster-vaccine","display_name":"booster vaccine","score":0.6690000295639038},{"id":"https://openalex.org/keywords/vaccine-safety-and-tolerability","display_name":"vaccine safety and tolerability","score":0.9010000228881836},{"id":"https://openalex.org/keywords/immunogenicity","display_name":"immunogenicity","score":0.8669999837875366},{"id":"https://openalex.org/keywords/neutralizing-antibodies","display_name":"neutralizing antibodies","score":0.9559999704360962},{"id":"https://openalex.org/keywords/anti-rbd-igg","display_name":"anti-RBD IgG","score":0.7870000004768372},{"id":"https://openalex.org/keywords/interferon-gamma-response","display_name":"interferon-gamma response","score":0.6669999957084656},{"id":"https://openalex.org/keywords/th2-polarization","display_name":"Th2 polarization","score":0.8019999861717224},{"id":"https://openalex.org/keywords/dose-escalation","display_name":"dose escalation","score":0.5860000252723694},{"id":"https://openalex.org/keywords/preexisting-immunity","display_name":"pre-existing immunity","score":0.6060000061988831}],"concepts":[{"id":"https://openalex.org/C2779053233","wikidata":"https://www.wikidata.org/wiki/Q731235","display_name":"ELISPOT","level":4,"score":0.8489000201225281},{"id":"https://openalex.org/C2780868878","wikidata":"https://www.wikidata.org/wiki/Q1660197","display_name":"Immunogenicity","level":3,"score":0.8019999861717224},{"id":"https://openalex.org/C2778375690","wikidata":"https://www.wikidata.org/wiki/Q7814214","display_name":"Tolerability","level":3,"score":0.6279000043869019},{"id":"https://openalex.org/C71924100","wikidata":"https://www.wikidata.org/wiki/Q11190","display_name":"Medicine","level":0,"score":0.5562999844551086},{"id":"https://openalex.org/C203014093","wikidata":"https://www.wikidata.org/wiki/Q101929","display_name":"Immunology","level":1,"score":0.48649999499320984},{"id":"https://openalex.org/C197934379","wikidata":"https://www.wikidata.org/wiki/Q2047938","display_name":"Adverse effect","level":2,"score":0.43299999833106995},{"id":"https://openalex.org/C27081682","wikidata":"https://www.wikidata.org/wiki/Q269829","display_name":"Placebo","level":3,"score":0.4074999988079071},{"id":"https://openalex.org/C98274493","wikidata":"https://www.wikidata.org/wiki/Q128406","display_name":"Pharmacology","level":1,"score":0.38760000467300415},{"id":"https://openalex.org/C22889606","wikidata":"https://www.wikidata.org/wiki/Q2166189","display_name":"Antibody titer","level":4,"score":0.3732999861240387},{"id":"https://openalex.org/C159654299","wikidata":"https://www.wikidata.org/wiki/Q79460","display_name":"Antibody","level":2,"score":0.3711000084877014},{"id":"https://openalex.org/C8891405","wikidata":"https://www.wikidata.org/wiki/Q1059","display_name":"Immune system","level":2,"score":0.3531000018119812},{"id":"https://openalex.org/C12590561","wikidata":"https://www.wikidata.org/wiki/Q2920497","display_name":"Booster dose","level":4,"score":0.3312999904155731},{"id":"https://openalex.org/C32611913","wikidata":"https://www.wikidata.org/wiki/Q2166189","display_name":"Titer","level":3,"score":0.3156000077724457},{"id":"https://openalex.org/C2779261636","wikidata":"https://www.wikidata.org/wiki/Q7003054","display_name":"Neutralizing antibody","level":3,"score":0.31119999289512634},{"id":"https://openalex.org/C195616568","wikidata":"https://www.wikidata.org/wiki/Q128711","display_name":"Epitope","level":3,"score":0.29510000348091125},{"id":"https://openalex.org/C185592680","wikidata":"https://www.wikidata.org/wiki/Q2329","display_name":"Chemistry","level":0,"score":0.2827000021934509},{"id":"https://openalex.org/C126322002","wikidata":"https://www.wikidata.org/wiki/Q11180","display_name":"Internal medicine","level":1,"score":0.2703999876976013},{"id":"https://openalex.org/C2778715236","wikidata":"https://www.wikidata.org/wiki/Q55622662","display_name":"Discontinuation","level":2,"score":0.2578999996185303},{"id":"https://openalex.org/C535046627","wikidata":"https://www.wikidata.org/wiki/Q30612","display_name":"Clinical trial","level":2,"score":0.25619998574256897},{"id":"https://openalex.org/C31760486","wikidata":"https://www.wikidata.org/wiki/Q7180990","display_name":"Phases of clinical research","level":3,"score":0.25209999084472656}],"mesh":[{"descriptor_ui":"D000086382","descriptor_name":"COVID-19","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D000086382","descriptor_name":"COVID-19","qualifier_ui":"Q000517","qualifier_name":"prevention & control","is_major_topic":true},{"descriptor_ui":"D000086402","descriptor_name":"SARS-CoV-2","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D000086663","descriptor_name":"COVID-19 Vaccines","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D000086663","descriptor_name":"COVID-19 Vaccines","qualifier_ui":"Q000009","qualifier_name":"adverse effects","is_major_topic":true},{"descriptor_ui":"D000086663","descriptor_name":"COVID-19 Vaccines","qualifier_ui":"Q000276","qualifier_name":"immunology","is_major_topic":true},{"descriptor_ui":"D000097007","descriptor_name":"Nanovaccines","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D000328","descriptor_name":"Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004305","descriptor_name":"Dose-Response Relationship, Drug","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D004311","descriptor_name":"Double-Blind Method","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D005260","descriptor_name":"Female","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D006801","descriptor_name":"Humans","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008297","descriptor_name":"Male","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D008875","descriptor_name":"Middle Aged","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012333","descriptor_name":"RNA, Messenger","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D012822","descriptor_name":"Silicon Dioxide","qualifier_ui":"Q000008","qualifier_name":"administration & dosage","is_major_topic":true},{"descriptor_ui":"D012822","descriptor_name":"Silicon Dioxide","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D016062","descriptor_name":"Porosity","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D053758","descriptor_name":"Nanoparticles","qualifier_ui":"Q000737","qualifier_name":"chemistry","is_major_topic":true},{"descriptor_ui":"D055815","descriptor_name":"Young Adult","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D056910","descriptor_name":"Republic of Korea","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false},{"descriptor_ui":"D064368","descriptor_name":"Healthy Volunteers","qualifier_ui":null,"qualifier_name":null,"is_major_topic":false}],"locations_count":5,"locations":[{"id":"doi:10.2147/dddt.s631473","doi":"https://doi.org/10.2147/dddt.s631473","is_oa":true,"landing_page_url":"https://doi.org/10.2147/dddt.s631473","pdf_url":"https://www.dovepress.com/article/download/121547","source":{"id":"https://openalex.org/S2496126384","display_name":"Drug Design Development and Therapy","issn_l":"1177-8881","issn":["1177-8881"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Design, Development and Therapy","raw_type":"journal-article"},{"id":"pmh:oai:pubmedcentral.nih.gov:13729766","doi":null,"is_oa":true,"landing_page_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13729766/","pdf_url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC13729766/pdf/DDDT-20-631473.pdf","source":{"id":"https://openalex.org/S2764455111","display_name":"PubMed Central","issn_l":null,"issn":null,"is_oa":true,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Des Devel Ther","raw_type":"Text"},{"id":"pmid:42979471","doi":null,"is_oa":false,"landing_page_url":"https://pubmed.ncbi.nlm.nih.gov/42979471","pdf_url":null,"source":{"id":"https://openalex.org/S4306525036","display_name":"PubMed","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":"https://openalex.org/I1299303238","host_organization_name":"National Institutes of Health","host_organization_lineage":["https://openalex.org/I1299303238"],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug design, development and therapy","raw_type":"Journal Article"},{"id":"pmh:oai:doaj.org/article:d9eecced8e274468a6522fcb8e68e026","doi":null,"is_oa":false,"landing_page_url":"https://doaj.org/article/d9eecced8e274468a6522fcb8e68e026","pdf_url":null,"source":{"id":"https://openalex.org/S4306401280","display_name":"DOAJ (DOAJ: Directory of Open Access Journals)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":null,"license_id":null,"version":"acceptedVersion","is_accepted":true,"is_published":false,"raw_source_name":"Drug Design, Development and Therapy, Vol Volume 20, Iss Issue 1, Pp 1-15 (2026)","raw_type":"article"},{"id":"pmh:oai:dovepress.com/121547","doi":null,"is_oa":true,"landing_page_url":"https://www.dovepress.com/first-in-human-phase-1-evaluation-of-the-degradaball-mesoporous-silica-peer-reviewed-fulltext-article-DDDT","pdf_url":null,"source":{"id":"https://openalex.org/S4306401012","display_name":"Dove Medical Press (Taylor and Francis Group)","issn_l":null,"issn":null,"is_oa":false,"is_in_doaj":false,"is_core":false,"listed_in":[],"host_organization":null,"host_organization_name":null,"host_organization_lineage":[],"host_organization_lineage_names":[],"type":"repository"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"submittedVersion","is_accepted":false,"is_published":false,"raw_source_name":null,"raw_type":"Clinical Trial Report"}],"best_oa_location":{"id":"doi:10.2147/dddt.s631473","doi":"https://doi.org/10.2147/dddt.s631473","is_oa":true,"landing_page_url":"https://doi.org/10.2147/dddt.s631473","pdf_url":"https://www.dovepress.com/article/download/121547","source":{"id":"https://openalex.org/S2496126384","display_name":"Drug Design Development and Therapy","issn_l":"1177-8881","issn":["1177-8881"],"is_oa":true,"is_in_doaj":true,"is_core":true,"listed_in":["cwts-core","doaj","dongbi-c","medline","norway-1","poland-70","russia-white-list-1","vabb-shw"],"host_organization":"https://openalex.org/P4310320348","host_organization_name":"Dove Medical Press","host_organization_lineage":["https://openalex.org/P4310320348","https://openalex.org/P4310320547"],"host_organization_lineage_names":["Dove Medical Press","Taylor & Francis"],"type":"journal"},"license":"cc-by-nc","license_id":"https://openalex.org/licenses/cc-by-nc","version":"publishedVersion","is_accepted":true,"is_published":true,"raw_source_name":"Drug Design, Development and Therapy","raw_type":"journal-article"},"sustainable_development_goals":[{"id":"https://metadata.un.org/sdg/3","display_name":"Good health and well-being","score":0.9940000176429749}],"study_designs":[{"id":"https://openalex.org/study-designs/randomized-controlled-trial","display_name":"Randomized Controlled Trial"},{"id":"https://openalex.org/study-designs/clinical-trial","display_name":"Clinical Trial"}],"awards":[],"funders":[{"id":"https://openalex.org/F4320316507","display_name":"Coalition for Epidemic Preparedness Innovations","ror":"https://ror.org/02j9wvt50"},{"id":"https://openalex.org/F4320321292","display_name":"Seoul National University","ror":"https://ror.org/04h9pn542"},{"id":"https://openalex.org/F4320322557","display_name":"Seoul National University Hospital","ror":"https://ror.org/01z4nnt86"}],"has_content":{"grobid_xml":true,"pdf":true},"content_urls":{"pdf":"https://content.openalex.org/works/W7224680461.pdf","grobid_xml":"https://content.openalex.org/works/W7224680461.grobid-xml"},"referenced_works_count":22,"referenced_works":["https://openalex.org/W2493005096","https://openalex.org/W2527863850","https://openalex.org/W3008398378","https://openalex.org/W3042833857","https://openalex.org/W3148255637","https://openalex.org/W3164002264","https://openalex.org/W3209735640","https://openalex.org/W3217355073","https://openalex.org/W4200287300","https://openalex.org/W4210777453","https://openalex.org/W4293543389","https://openalex.org/W4304187487","https://openalex.org/W4306153875","https://openalex.org/W4311582042","https://openalex.org/W4320921320","https://openalex.org/W4360601090","https://openalex.org/W4392059708","https://openalex.org/W4400694427","https://openalex.org/W4403545203","https://openalex.org/W4408750937","https://openalex.org/W4409070636","https://openalex.org/W4411193805"],"related_works":["https://openalex.org/W7203933356","https://openalex.org/W7125910358","https://openalex.org/W4392503839","https://openalex.org/W4385813617","https://openalex.org/W4384925739","https://openalex.org/W4390763808","https://openalex.org/W3122312485","https://openalex.org/W4221113218","https://openalex.org/W6902259009","https://openalex.org/W3201378864"],"abstract_inverted_index":{"Purpose:":[0],"mRNA":[1,35,55,209,280],"vaccines":[2],"require":[3,271],"an":[4,34,216,254],"effective":[5],"delivery":[6,50],"system":[7,51],"for":[8],"intracellular":[9],"uptake,":[10],"and":[11,17,29,57,96,103,114,144,171,174,197,248,265],"alternative":[12],"carriers":[13],"with":[14,44,123,138,207,240,249],"improved":[15],"stability":[16,56],"tolerability":[18],"remain":[19],"of":[20,32,75,105,155,227,235,278],"continued":[21],"interest.":[22,107],"This":[23],"study":[24],"evaluated":[25],"the":[26,201,221,261],"safety,":[27],"tolerability,":[28],"exploratory":[30,250],"immunogenicity":[31,109],"LEM-mR203,":[33],"SARS-CoV-2":[36],"receptor":[37],"binding":[38],"domain":[39],"(RBD)":[40],"booster":[41,233],"vaccine":[42,210],"formulated":[43],"DegradaBALL,":[45],"a":[46,63,71,193],"mesoporous":[47],"silica":[48],"nanoparticle-based":[49],"developed":[52],"to":[53,86],"improve":[54],"enable":[58],"localized":[59],"delivery.":[60],"Methods:":[61],"In":[62,178],"randomized,":[64],"double-blind,":[65],"placebo-controlled,":[66],"dose-escalation":[67],"phase":[68],"1":[69],"study,":[70],"single":[72,232],"intramuscular":[73],"dose":[74,136,234],"LEM-mR203":[76,130,236],"(40":[77],"\u03bcg":[78,223],"or":[79,82,153],"100":[80,222],"\u03bcg)":[81],"placebo":[83,172],"was":[84,131,187,237],"administered":[85],"20":[87],"healthy":[88],"Korean":[89],"adult":[90],"volunteers.":[91],"Safety":[92],"endpoints":[93],"included":[94],"solicited":[95,146],"unsolicited":[97],"adverse":[98],"events":[99],"(AEs),":[100],"serious":[101,151],"AEs,":[102,152],"AEs":[104,154],"special":[106,156],"Exploratory":[108,212],"comprised":[110],"anti-RBD":[111,185],"antibody":[112,116],"concentrations":[113],"neutralizing":[115],"(Nab)":[117],"titers":[118,199],"through":[119,189],"Day":[120,190],"366,":[121],"together":[122],"interferon-\u03b3":[124],"(IFN-\u03b3)/interleukin-4":[125],"(IL-4)":[126],"ELISpot":[127,213],"responses.":[128],"Results:":[129],"well":[132,238],"tolerated":[133],"at":[134],"both":[135],"levels,":[137],"mild":[139],"(Grade":[140],"1)":[141],"injection-site":[142],"reactions":[143],"infrequent":[145],"systemic":[147],"AEs;":[148],"no":[149,241],"fever,":[150],"interest":[157],"were":[158],"reported.":[159],"Transient,":[160],"asymptomatic":[161],"decreases":[162],"in":[163,220,273],"white":[164],"blood":[165],"cell":[166],"count":[167],"occurred":[168],"across":[169],"active":[170],"groups":[173],"resolved":[175],"without":[176,192,225,257],"sequelae.":[177],"this":[179],"pre-immune":[180],"cohort":[181],"(85%":[182],"anti-nucleocapsid":[183],"reactive),":[184],"IgG":[186],"maintained":[188],"366":[191,246],"clear":[194],"booster-induced":[195],"increase":[196],"Nab":[198],"against":[200],"Kappa":[202],"variant":[203],"(B.1.617.1)":[204],"waned,":[205],"consistent":[206],"known":[208],"kinetics.":[211],"results":[214],"suggested":[215],"IFN-\u03b3-oriented":[217,255],"cellular":[218,251],"response":[219],"group,":[224],"evidence":[226],"IL-4/Th2":[228],"skewing.":[229,259],"Conclusion:":[230],"A":[231],"tolerated,":[239],"major":[242],"safety":[243],"concerns":[244],"over":[245],"days,":[247],"responses":[252],"suggesting":[253],"profile":[256],"Th2":[258],"Given":[260],"small":[262],"sample":[263],"size":[264],"high":[266],"pre-existing":[267],"immunity,":[268],"these":[269],"findings":[270],"confirmation":[272],"larger,":[274],"adequately":[275],"powered":[276],"studies":[277],"DegradaBALL-based":[279],"vaccines.":[281]},"counts_by_year":[],"updated_date":"2026-11-08T12:12:28.789561","created_date":"2026-10-30T00:00:00"}